Aim: To evaluate the efficacy and safety of the vaginal-specific lactobacilli strain in management of bacterial vaginosis (BV). Materials and methods: A nonrandomized, open-labeled, noncomparative, multicentric study was conducted in a total of 58 female patients suffering from BV. Each patient was administered a combination of four strains of lactobacilli. Vaginal pH, discharge, odor, itching, and painful urination were performed at baseline, week 2, and week 4 as assessment parameters. Results: At the end of the study, data were extractable in only 56 females (mean age was 34.57 ± 11 years). Associated BV symptoms like vaginal discharge, odor, and painful urination reduced significantly at week 4 as compared to baseline. The most frequently encountered symptoms were vaginal discharge, vaginal pH, odor, and itching. With a shift in pH < 4.5, at the end of week 4 all females showed improvement in the vaginal microbiota. Tolerability of fixed-dose combination was found to be good and none of the subjects discontinued the treatment. Conclusion: Probiotic combination of vaginal-specific probiotic strains was found to be effective and safe for use in females who suffer from BV. Clinical significance: Lactobacilli have been found in very low numbers in women suffering from BV. After supplementing probiotic, mere fall in pH < 4.5 indicates probable colonization of the vagina with a specific strain of lactobacilli has helped in production of lactic acid and restoration of the vaginal microflora.
Vulvovaginal infections; viewed and dated on Feb 21, 2019. https://www.cedars-sinai.edu/Patients/Health-Conditions/Vulvovaginal-Infections.aspx.
Amit Singh, Vaibhav Kanti, Seema Dayal, et al. Prevalence and risk factors of bacterial vaginosis among women of reproductive age attending rural tertiary care institute of western Uttar Pradesh. J Evolution Med Dent Sci 2016;5(43):2695–2701. DOI: 10.14260/jemds/2016/630.
Bacteria vaginosis (CDC, centers for disease control and prevention); viewed and dated on Feb 21, 2019. https://www.cdc.gov/std/tg2015/bv.htm.
Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 2004;80(1):8–11. DOI: 10.1136/sti.2002.002733.
McClelland RS, Richardson BA, Hassan WM, et al. A prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis 2009;199(12):1883–1890. DOI: 10.1086/599213.
Marschalek J, Farr A, Marie-Louise M, et al. Influence of orally administered probiotic lactobacillus strains on vaginal microbiota in women with breast cancer during chemotherapy: a randomized placebo-controlled double-blinded pilot study. Breast Care (Basel) 2017;12(5):335–339.
Reid G, Bruce AW. Urogenital infections in women: can probiotics help? Postgrad Med J 2003;79(934):428–432. DOI: 10.1136/pmj.79.934.428.
Akgül T, Karakan T. The role of probiotics in women with recurrent urinary tract infections. Turk J Urol 2018;44(5):377–383. DOI: 10.5152/tud.2018.48742.
Swaminathan KR, Devi M, Gerald S, et al. Prevalence of vulvovaginal candidiasis in the women of the reproductive age, in rural India. Int J Clin Obstet Gynae 2017;1(2):37–39.
Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: how promising is the use of Probiotics? Indian J Med Microbiol 2017;35(3):347–354. DOI: 10.4103/ijmm.IJMM_16_292.
Astarte (HSO Health Care GmbH) Viewed and dated on Feb 21, 2019; http://www.astarte-probiotics.com/studies.
Kaufmann U, Domig KJ, Lippitsch CI, et al. Ability of an orally administered lactobacilli preparation to improve the quality of the neovaginal microflora in male to female transsexual women. Eur J Obstet Gynecol Reprod Biol 2014;172:102–105. DOI: 10.1016/j.ejogrb.2013.10.019.